FDA Acne Guidance Recommends Selection Of Lesion Type Prior To Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sponsors developing acne drugs should specify the type of lesion an investigational drug is intended to treat prior to beginning Phase III studies, FDA recommends in a recent draft guidance.
You may also be interested in...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product
Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class